Rigontec picks up Series A funds

Germany-based Rigontec, which focuses on RIG-I targeting RNA therapeutics, has raised 15 million euros in Series A funding. The investors included Boehringer Ingelheim Venture Fund, Forbion Capital Partners, High-Tech Gründerfonds, Sunstone Capital and Wellington Partners Life Sciences.

North AmericaUSBriefs